233 related articles for article (PubMed ID: 23467907)
1. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.
Marchion DC; Bicaku E; Xiong Y; Bou Zgheib N; Al Sawah E; Stickles XB; Judson PL; Lopez AS; Cubitt CL; Gonzalez-Bosquet J; Wenham RM; Apte SM; Berglund A; Lancaster JM
Oncol Rep; 2013 May; 29(5):2011-8. PubMed ID: 23467907
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.
Quinn JM; Greenwade MM; Palisoul ML; Opara G; Massad K; Guo L; Zhao P; Beck-Noia H; Hagemann IS; Hagemann AR; McCourt CK; Thaker PH; Powell MA; Mutch DG; Fuh KC
Mol Cancer Ther; 2019 Feb; 18(2):389-398. PubMed ID: 30478151
[TBL] [Abstract][Full Text] [Related]
3. In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival.
Bicaku E; Xiong Y; Marchion DC; Chon HS; Stickles XB; Chen N; Judson PL; Hakam A; Gonzalez-Bosquet J; Wenham RM; Apte SM; Fulp W; Cubitt CL; Chen DT; Lancaster JM
Br J Cancer; 2012 Jun; 106(12):1967-75. PubMed ID: 22596241
[TBL] [Abstract][Full Text] [Related]
4. Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells.
Dasari VR; Carey DJ; Gogoi R
BMC Cancer; 2020 Apr; 20(1):273. PubMed ID: 32245422
[TBL] [Abstract][Full Text] [Related]
5. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
6. Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells.
Stamelos VA; Robinson E; Redman CW; Richardson A
Gynecol Oncol; 2013 Feb; 128(2):377-82. PubMed ID: 23168176
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.
Teoh D; Ayeni TA; Rubatt JM; Adams DJ; Grace L; Starr MD; Barry WT; Berchuck A; Murphy SK; Secord AA
Gynecol Oncol; 2011 Apr; 121(1):187-92. PubMed ID: 21208651
[TBL] [Abstract][Full Text] [Related]
8. CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells.
Deying W; Feng G; Shumei L; Hui Z; Ming L; Hongqing W
Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28258248
[TBL] [Abstract][Full Text] [Related]
9. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
[TBL] [Abstract][Full Text] [Related]
10. Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment.
Kwon Y; Smith BD; Zhou Y; Kaufman MD; Godwin AK
Oncogene; 2015 Jan; 34(2):144-53. PubMed ID: 24362531
[TBL] [Abstract][Full Text] [Related]
11. HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma.
Bu R; Uddin S; Bavi P; Hussain AR; Al-Dayel F; Ghourab S; Ahmed M; Al-Kuraya KS
Lab Invest; 2011 Jan; 91(1):124-37. PubMed ID: 20661229
[TBL] [Abstract][Full Text] [Related]
12. In Ovarian Cancer Multicellular Spheroids, Platelet Releasate Promotes Growth, Expansion of ALDH+ and CD133+ Cancer Stem Cells, and Protection against the Cytotoxic Effects of Cisplatin, Carboplatin and Paclitaxel.
Casagrande N; Borghese C; Agostini F; Durante C; Mazzucato M; Colombatti A; Aldinucci D
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809553
[TBL] [Abstract][Full Text] [Related]
13. Cooperative Effect of Oncogenic
Liu S; Li S; Wang B; Liu W; Gagea M; Chen H; Sohn J; Parinyanitikul N; Primeau T; Do KA; Vande Woude GF; Mendelsohn J; Ueno NT; Mills GB; Tripathy D; Gonzalez-Angulo AM
Mol Cancer Ther; 2019 Feb; 18(2):399-412. PubMed ID: 30518672
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
15. The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas.
Jain HV; Meyer-Hermann M
Cancer Res; 2011 Feb; 71(3):705-15. PubMed ID: 21169413
[TBL] [Abstract][Full Text] [Related]
16. Nilotinib in combination with carboplatin and paclitaxel is a candidate for ovarian cancer treatment.
Weigel MT; Rath K; Alkatout I; Wenners AS; Schem C; Maass N; Jonat W; Mundhenke C
Oncology; 2014; 87(4):232-45. PubMed ID: 25116401
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration.
Chattopadhyay C; Grimm EA; Woodman SE
PLoS One; 2014; 9(2):e83957. PubMed ID: 24551032
[TBL] [Abstract][Full Text] [Related]
18. PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
Goodwin CR; Lal B; Ho S; Woodard CL; Zhou X; Taeger A; Xia S; Laterra J
Anticancer Drugs; 2011 Oct; 22(9):905-12. PubMed ID: 21654317
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial.
Rob L; Cibula D; Knapp P; Mallmann P; Klat J; Minar L; Bartos P; Chovanec J; Valha P; Pluta M; Novotny Z; Spacek J; Melichar B; Kieszko D; Fucikova J; Hrnciarova T; Korolkiewicz RP; Hraska M; Bartunkova J; Spisek R
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34992091
[TBL] [Abstract][Full Text] [Related]
20. Quinacrine in endometrial cancer: Repurposing an old antimalarial drug.
Kalogera E; Roy D; Khurana A; Mondal S; Weaver AL; He X; Dowdy SC; Shridhar V
Gynecol Oncol; 2017 Jul; 146(1):187-195. PubMed ID: 28545688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]